Corium International, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $7.3M | $7.0M | $40.9M | $42.4M | $50.3M | $42.9M |
| Operating income | −$39.8M | −$28.9M | −$21.0M | −$10.1M | $1.2M | −$810,000 |
| Net income | −$11.0M | −$10.5M | −$28.4M | −$9.9M | −$13.9M | −$5.4M |
| Total assets | $84.9M | $67.2M | $100.2M | $65.7M | $44.0M | — |
| Total liabilities | $68.6M | $64.3M | $64.9M | $53.9M | $102.6M | — |
| Equity | $16.2M | $2.9M | $35.3M | $11.8M | −$119.1M | −$106.3M |
| EPS (diluted) | — | — | — | $0.33 | $-0.94 | — |
| Shares out. | 36.1M | 22.5M | 22.2M | 18.1M | 1.9M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −541.3%
- Net margin
- −150.3%
- Return on equity
- −68.1%
- Return on assets
- −13.0%
- Return on capital (ROCE)
- −65.7%
- Liabilities / assets
- 80.9%
- Debt / equity
- 4.23×
- Book value / share
- $0.45
- Revenue growth (YoY)
- 5.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- -7.98distress
- Accruals / assets
- 30.8%high accruals
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- High accruals — earnings-quality risk
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Essex Woodlands Health Ventures Fund Vii Lp10% owner | Nov 27, 2018 | U | 9.4M | $12.50 |
| Eastman Ronald WDirector | Nov 27, 2018 | U | 9.4M | $12.50 |
| Sweemer Timothy DOfficer — Chief Accounting Officer | Nov 27, 2018 | D | 34,801 | $12.50 |
| Staple Peter DOfficer — President & CEO | Nov 27, 2018 | D | 291,397 | $12.50 |
| Singh ParminderOfficer — CTO & Vice President, R&D | Nov 27, 2018 | D | 16,127 | $12.50 |
| Sarret Joseph J.Officer — Chief Business Officer | Nov 27, 2018 | D | 16,689 | $12.50 |
| Greenwood DavidDirector | Nov 27, 2018 | D | 3,000 | $12.50 |
| Gardner PhyllisDirector | Nov 27, 2018 | D | 34,203 | $12.50 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventNov 27, 2018
- Director / officer changeNov 15, 2018
- Entered a material agreement · Other material eventOct 11, 2018
- Results of operationsAug 9, 2018
- Results of operationsMay 14, 2018
- Other material eventMar 27, 2018
- Shareholder voteMar 20, 2018
- New financial obligation · Unregistered equity saleMar 16, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.